Different pathways are involved in arsenic-trioxide-induced cell proliferation and growth inhibition in human

X Bi1, J Gu, Z Guo

  • 1Department of Dermatology, Changhai Hospital, Second Military Medical University, Shanghai, PR China.

Abstract

Insights

Arsenic trioxide (As(2)O(3)) shows dual effects: low doses promote keratinocyte proliferation, while high doses induce apoptosis and cell cycle arrest. Skin carcinoma cells, however, are resistant to As(2)O(3) growth inhibition.

Area of Science:

  • Toxicology
  • Molecular Biology
  • Dermatology

Background:

  • Arsenic is a known carcinogen linked to skin cancer.
  • Arsenic trioxide (As(2)O(3)) exhibits potential anticancer properties.
  • The mechanisms behind arsenic's opposing effects on skin cells are not fully understood.

Purpose of the Study:

  • To investigate the effects of As(2)O(3) on keratinocyte proliferation and growth inhibition.
  • To explore the molecular pathways influenced by As(2)O(3) in normal and cancerous skin cells.

Main Methods:

  • Utilized normal human keratinocytes (NHK), HaCaT cells, and A431 epidermal carcinoma cells.
  • Exposed cells to varying concentrations of As(2)O(3) (0.5-32 nM and 0.5-10 microM).
  • Assessed cell proliferation, gene expression, apoptosis (caspase-3 activation), and cell cycle progression (G2-M arrest).

Main Results:

  • Low As(2)O(3) concentrations (0.5-32 nM) enhanced keratinocyte proliferation and upregulated cell cycling genes (e.g., CDK4, E2F1).
  • High As(2)O(3) concentrations (0.5-10 microM) inhibited NHK and HaCaT cell growth, induced apoptosis via caspase-3, and caused G2-M cell cycle arrest.
  • A431 skin carcinoma cells demonstrated resistance to As(2)O(3)-induced growth inhibition and apoptosis.

Conclusions:

  • As(2)O(3) exerts differential effects on skin cells, promoting proliferation at low doses and inducing cell death at high doses.
  • Skin carcinoma cells exhibit resistance to the cytotoxic effects of As(2)O(3).
  • As(2)O(3) may not be a suitable therapeutic agent for treating skin carcinomas due to observed resistance.

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...